REVIEW

Multiple roles of COUP-TFII in cancer initiation and progression

Lacey M Litchfield and Carolyn M Klinge

Department of Biochemistry and Molecular Biology, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA

(Correspondence should be addressed to C M Klinge; Email: carolyn.klinge@louisville.edu)

Abstract

Chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) is an orphan nuclear receptor that acts as a transcriptional activator or repressor in a cell type-dependent manner. Best characterized for its role in the regulation of angiogenesis during mouse development, COUP-TFII also plays important roles in glucose metabolism and cancer. Expression of COUP-TFII is altered in various endocrine conditions. Cell type-specific functions and the regulation of COUP-TFII expression result in its varying physiological and pathological actions in diverse systems. Evidence will be reviewed for oncogenic and tumor-suppressive functions of COUP-TFII, with roles in angiogenesis, metastasis, steroidogenesis, and endocrine sensitivity of breast cancer described. The applicability of current data to our understanding of the role of COUP-TFII in cancer will be discussed.

Journal of Molecular Endocrinology (2012) **49**, R135–R148

Introduction

Steroid hormones and nuclear receptor (NR) ligands play critical roles in cancer initiation and progression, and their antagonists have proven efficacy in the treatment and prevention of cancers. This is most notable in breast and prostate cancers and the use of all-*trans* retinoic acid (RA) for acute promyelocytic leukemia (Risbridger *et al.* 2010, Siddikuzzaman *et al.* 2011). Steroid/NRs act as ligand-activated transcription factors to either positively or negatively regulate gene expression (Stanisic *et al.* 2010, Ahmad & Kumar 2011). Activation of NRs occurs through binding a variety of ligands including hormones and vitamins/retinoids. NRs have physiological roles to modulate gene expression during development and growth. As alteration of basal gene expression leads to many pathogenic outcomes, including cancer, maintenance of normal gene expression by NRs is vital. One such critical NR is chicken ovalbumin upstream promoter transcription factor II (COUP-TFII). From the time of the identification of the COUP-TF family in 1986 (Sagami *et al.* 1986), the many functions of COUP-TFs have continued to be explored. The role of COUP-TFII in cancer is widely debated with evidence linking COUP-TFII to both tumor-suppressive and oncogenic functions. This review will explore both the regulation and function of COUP-TFII and its connections to cancer.

COUP-TFI and COUP-TFII

The COUP-TF family consists of two highly homologous subtypes, COUP-TFI and COUP-TFII, located on human chromosomes 5 and 15 respectively (Fig. 1). COUP-TFs have been previously reviewed (Tsai & Tsai 1997, Lin *et al.* 2011), but not in the specific context of separating COUP-TFI and COUP-TFII in cancer. COUP-TFs are ancient NRs and are located close to retinoid X receptors (RXRs) in the evolutionary tree (Thornton 2001, Thornton *et al.* 2003). As evolutionarily conserved transcription factors, COUP-TFs have major roles in development. The importance of COUP-TFII expression is evidenced by studies in knockout mice (Pereira *et al.* 1999). Homozygous mutation of *COUP-TFII* (*Nr2f2*) leads to embryonic lethality due to impaired angiogenesis and heart defects, resulting in hemorrhage and edema. These effects may in part be explained by the reduction in angiopoietin-1 (Ang-1) expression in COUP-TFII-null mice (Pereira *et al.* 1999). Other important embryonic roles for COUP-TFII include regulation of limb growth and muscle development (Lee *et al.* 2004). COUP-TFII-null mice display a reduction in expression of *Lbx1*, a protein required for proper muscle precursor cell migration, and in myogenin, which is necessary for muscle cell differentiation (Lee *et al.* 2004, Vasyutina & Birchmeier 2006).

Figure 1 Comparison of COUP-TFI and COUP-TFII protein homology. COUP-TFI (NP_005645.1) and COUP-TFII (NP_066285.1) amino acid sequences were obtained from the National Center for Biotechnology Information. The COUP-TF DNA binding domains (DBD) and ligand-binding domains (LBD) share 99 and 97% amino acid homology respectively. Positions noted as important in coactivator recognition are shown in orange.

Based on the high-sequence identity in their DNA binding domains (Fig. 1), we anticipate that COUP-TFI and COUP-TFII regulate the same genes. However, this has not been empirically tested and it is worth noting that the N-terminus is divergent (Fig. 1) and immunoprecipitation studies indicate differences in proteins interacting with COUP-TFI (Zhang *et al.* 2009) and COUP-TFII (Litchfield *et al.* 2012), although, again, this has not been systematically studied in cells in which both are expressed. COUP-TFI and COUP-TFII may have divergent functions in certain contexts as well. Differences in COUP-TFI and COUP-TFII function in breast cancer endocrine sensitivity, for example, have also been identified (Riggs *et al.* 2006). This review will focus specifically on COUP-TFII.

COUP-TFII regulation of gene expression

Mechanisms of regulation

COUP-TFII can activate or repress gene expression in both a tissue-specific and gene-specific manner through mechanisms involving direct binding to DNA response elements or binding to other transcription factors. Through binding to 5'-AGGTCA-3' direct repeats (DRs) with variable spacing (Kliwer *et al.* 1992), COUP-TFII modulates the expression of target genes. Specific genes upon which COUP-TFII activates transcription include RA receptor $\beta 2$ (RAR $\beta 2$, *RARB2*; Lin *et al.* 2000, Litchfield *et al.* 2012), phosphoenolpyruvate carboxykinase (PEPCK, *PCK1*; De Martino *et al.* 2004b), *NGFI-A* (*Egr1*; Pipaon *et al.* 1999, Kruse *et al.* 2008), and cholesterol 7 α -hydroxylase (*CYP7A1*; Stroup & Chiang 2000). COUP-TFII action may be potentiated by interaction with coactivators such as steroid receptor coactivator family members SRC-1/NCOA1, SRC-2/NCOA2, and SRC-3/NCOA3 (Pipaon *et al.* 1999, Kruse *et al.* 2008), as well as PGC1 α (Kruse *et al.* 2008), p300/CBP (Pipaon *et al.* 1999), orphan receptor coactivator (ORCA; Marcus *et al.* 1996), and nucleolin (Litchfield *et al.* 2012). DNA binding of COUP-TFII can promote

the binding of a second transcription factor, further activating gene transcription. This occurs for both the *PCK1* and *Cyp7a1* genes, where COUP-TFII binding to the promoter recruits binding of glucocorticoid receptor (GR) to enhance gene expression (De Martino *et al.* 2004a,b). COUP-TFII can also bind to Sp1 sites to cooperatively activate gene expression, as was reported for regulation of *Otx2* expression during morphogenesis in the mouse eye (Tang *et al.* 2010).

Alternatively, binding of COUP-TFII to DRs may result in repression of gene expression. In the mechanism of 'active repression,' COUP-TFII binding results in recruitment of corepressors, i.e. nuclear corepressor (NCoR; Bailey *et al.* 1997) and silencing mediator of retinoid and thyroid receptors (SMRTs; Shibata *et al.* 1997, Okamura *et al.* 2009), resulting in repressed chromatin structure and a corresponding blockade of target gene transcriptional activation. COUP-TFII interaction with SMRT represses *PPAR γ 1* (*Pparg1*) and *PPAR γ 2* (*Pparg2*) expression to suppress adipogenesis (Okamura *et al.* 2009). Repression of the human oxytocin promoter by COUP-TFII binding has also been reported (Chu & Zingg 1997). COUP-TFII represses *PAX6* expression in the retina via binding to a DR1 site (TGTTTCACAGTCCA; Tang *et al.* 2010).

Through an alternative mechanism of transrepression, COUP-TFII can interact with other NRs and transcription factors to inhibit their normal transcriptional activity. Examples of this include inhibition of ER- and GR-induced gene expression in a gene-specific manner (Klinge *et al.* 1997, De Martino *et al.* 2004b). COUP-TFII can also repress AP-1 signaling through interaction with c-Jun (Lin *et al.* 2002). Interaction of COUP-TFII with Runx2 inhibits osteoblast differentiation via blocking Runx2 binding to the osteocalcin promoter (Lee *et al.* 2012). Other mechanisms of repression involve the modulation of ER, RXR, PPAR, and VDR activity by competing for DNA response element binding or heterodimerization with the class II heterodimeric partner RXR (Cooney *et al.* 1993).

Table 1 List of COUP-TFII-regulated genes identified by Ingenuity Pathway Analysis

Gene (protein)	Name	Location	Family	Regulation by COUP-TFII	References
ALDH2	Aldehyde dehydrogenase 2 family (mitochondrial)	Cytoplasm	Enzyme	Decrease	You <i>et al.</i> (2002)
ANGPT1	Angiotensinogen 1	Extracellular space	Growth factor	Increase	Pereira <i>et al.</i> (1999)
APOA1	Apolipoprotein A-I	Extracellular space	Transporter	Decrease	Widom <i>et al.</i> (1992), Jiang <i>et al.</i> (1995) and Power & Cereghini (1996)
APOA4	Apolipoprotein A-IV	Extracellular space	Transporter	Decrease	Ochoa <i>et al.</i> (1993) and Sauvaget <i>et al.</i> (2002)
APOC3	Apolipoprotein C-III	Extracellular space	Transporter	Decrease	Mietus-Snyder <i>et al.</i> (1992), Power & Cereghini (1996), Kitstaki & Talianidis (1997) and Lavrentiadou <i>et al.</i> (1999)
CYP11B2	Aldosterone synthase, cytochrome P450, family 11, subfamily B, polypeptide 2	Cytoplasm	Enzyme	Increase	Shibata <i>et al.</i> (2004) and Kurihara <i>et al.</i> (2005)
CYP7A1	Cholesterol 7 alpha-hydroxylase, cytochrome P450, family 7, subfamily A, polypeptide 1	Cytoplasm	Enzyme	Increase	Stroup & Chiang (2000)
GATA6	GATA binding protein 6	Nucleus	Transcription regulator	Decrease suggested	Kyrmizi <i>et al.</i> (2006)
HBE1	Hemoglobin, epsilon 1	Cytoplasm	Transporter	Decrease	Tanimoto <i>et al.</i> (2000) and Liberati <i>et al.</i> (2001)
HNF1A	HNF1 homeobox A	Nucleus	Transcription regulator	Increase	Kitstaki & Talianidis (1997) and Kyrmizi <i>et al.</i> (2006)
HNF1B	HNF1 homeobox B	Nucleus	Transcription regulator	Increase	Power & Cereghini (1996)
HNF4A	Hepatocyte nuclear factor 4, alpha	Nucleus	Transcription regulator	Increase	Perilhou <i>et al.</i> (2008b)
KDR	VEGFR2; kinase insert domain receptor (a type III receptor tyrosine kinase)	Plasma membrane	Kinase	Decrease	Kang <i>et al.</i> (2010)
LIPC	Lipase, hepatic	Extracellular space	Enzyme	Decrease	Rufibach <i>et al.</i> (2006)
LPL	Lipoprotein lipase	Cytoplasm	Enzyme	Increase	Robinson <i>et al.</i> (1999)
LTF	Lactotransferrin	Extracellular space	Peptidase	Decrease	Lee <i>et al.</i> (1995)
NPPA	Natriuretic peptide A	Extracellular space	Other	Increase	Huggins <i>et al.</i> (2001)
NR0B1	Dax1, nuclear receptor subfamily 0, group B, member 1	Nucleus	Ligand-dependent nuclear receptor	Decrease	Yu <i>et al.</i> (1998)
NR1H4	FXR, nuclear receptor subfamily 1, group B, member 4	Nucleus	Ligand-dependent nuclear receptor	Unknown	Kyrmizi <i>et al.</i> (2006)
NR1I2	PXR, nuclear receptor subfamily 1, group I, member 2	Nucleus	Ligand-dependent nuclear receptor	Unknown	Kyrmizi <i>et al.</i> (2006)
NR5A2	LRH1, nuclear receptor subfamily 5, group A, member 2	Nucleus	Ligand-dependent nuclear receptor	Unknown	Kyrmizi <i>et al.</i> (2006)
NRP1	Neuropilin 1	Plasma membrane	Transmembrane receptor	Decrease	Kang <i>et al.</i> (2010)
PCK1	Phosphoenolpyruvate carboxykinase 1 (soluble)	Cytoplasm	Kinase	Decrease	Eubank <i>et al.</i> (2001)
POU5F1	Oct 4; POU class 5 homeobox 1	Nucleus	Transcription regulator	Decrease	Ben-Shushan <i>et al.</i> (1995) and Rosa & Brivanlou (2011)

(continued)

Table 1 Continued

Gene (protein)	Name	Location	Family	Regulation by COUP-TFII	References
PPARA	Peroxisome proliferator-activated receptor alpha	Nucleus	Ligand-dependent nuclear receptor	Decrease	Pineda Torra <i>et al.</i> (2002)
RARB	Retinoic acid receptor, β	Nucleus	Ligand-dependent nuclear receptor	Increase	Nakshatri & Chambon (1994), Wu <i>et al.</i> (1997), Lin <i>et al.</i> (2000) and Litchfield <i>et al.</i> (2012)
RBP2	Retinol binding protein 2, cellular	Cytoplasm	Transporter	Decrease	Nakshatri & Chambon (1994)
SHBG	Sex hormone-binding globulin	Extracellular space	Other	Decrease	Janne & Hammond (1998)
SLC9A1	Solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1	Plasma membrane	Ion channel	Increase	and Selva <i>et al.</i> (2005) Li <i>et al.</i> (2002)

Ingenuity Pathway Analysis

As summarized here, COUP-TFII regulates the expression of diverse gene targets. Table 1 contains a list of known COUP-TFII targets as identified using Ingenuity Pathway Analysis (IPA; Ingenuity Systems, www.ingenuity.com). These targets are also displayed in Fig. 2. COUP-TFII has varying effects on expression of other NRs and transcription factors. COUP-TFII increased the expression of HNF1 α (Ktistaki & Talianidis 1997), HNF1 β (Power & Cereghini 1996), HNF4 α (Perilhou *et al.* 2008b), and RAR β (Wu *et al.* 1997, Lin *et al.* 2000, Litchfield *et al.* 2012), while it decreased the expression of Oct4 (Ben-Shushan *et al.* 1995, Rosa & Brivanlou 2011), Dax1 (Yu *et al.* 1998), and PPAR α (Pineda Torra *et al.* 2002). As previously described, COUP-TFII has well-known functions in repressing the transcriptional activity of other NRs and transcription factors. Although COUP-TFII increases HNF4 expression, other reports highlight the repression of HNF4 function by COUP-TFII. Specifically, COUP-TFII decreases transcriptional activation of *ALDH2* (You *et al.* 2002) and retinol binding protein 2 (RBP2; Nakshatri & Chambon 1994) by HNF4. The HNF4 activation of hepatic lipase is suppressed by COUP-TFII (Rufibach *et al.* 2006), while lipoprotein lipase expression is induced by COUP-TFII synergistically with PPAR γ (Robinson *et al.* 1999), part of the many of reported functions of COUP-TFII in the cholesterol-processing pathway. A similar response occurs for apolipoproteins A-I, A-IV, and C-III, where COUP-TFII represses the RXR α -mediated expression of APOA-I (Widom *et al.* 1992, Jiang *et al.* 1995, Power & Cereghini 1996) and HNF4-mediated expression of APOA-IV (Ochoa *et al.* 1993, Sauvaget *et al.* 2002) and APOC-III (Mietus-Snyder *et al.* 1992, Power & Cereghini 1996, Ktistaki & Talianidis 1997, Lavrentiadou *et al.* 1999). HNF4 and COUP-TFII binding to the sex hormone binding globulin (*Shbg*) promoter was reported in murine Sertoli cells (Selva *et al.* 2005). SHBG expression is increased by HNF4 and suppressed by COUP-TF in HepG2 hepatoblastoma cells (Janne & Hammond 1998). Decreased SHBG expression is indicative of metabolic syndrome and may result in increased plasma androgen and estrogen levels, although the precise connection of COUP-TFII to these phenotypes has not been investigated (Hammond 2011).

Although COUP-TFII is classically known for its role in transrepression, COUP-TFII may also enhance the effect of a second NR. Induction of cytochrome P450 family members cholesterol 7 α -hydroxylase CYP7A1 (Stroup & Chiang 2000) and aldosterone synthase CYP11B2 (Shibata *et al.* 2004, Kurihara *et al.* 2005) by COUP-TFII was reported, with COUP-TFII and HNF4 acting to synergistically activate CYP7A1 (Stroup

Figure 2 COUP-TFII target genes. COUP-TFII has been reported to modulate the expression of a variety of target genes both positively and negatively. A list of COUP-TFII target genes and corresponding network pathway was generated using Ingenuity Pathway Analysis (IPA; Ingenuity Systems, www.ingenuity.com).

& Chiang 2000). CYP7A1 catalyzes the first step in the conversion of cholesterol to bile acid (Stroup & Chiang 2000), while CYP11B2 catalyzes the final steps of aldosterone synthesis (Kurihara *et al.* 2005), implying that COUP-TFII transcriptional activation would increase the production of bile acid and aldosterone.

As shown in Table 1 and Fig. 2, COUP-TFII opposes PPAR γ /RXR activation of *PEPCK* transcription in preadipocytes/fibroblasts, a result that was proposed to suppress adipogenesis (Eubank *et al.* 2001). COUP-TF also inhibited 9-*cis* RA/RXR-induced activation of the lactotransferrin promoter in transiently transfected ZR-75-1 and Hs578T breast cancer cells apparently by competing for DNA binding to a composite RARE/ERE in the gene promoter (Lee *et al.* 1995). Concurrent binding of COUP-TFII and NF-Y to the hemoglobin epsilon promoter leads to a repression of gene expression (Liberati *et al.* 2001). In addition to the targets identified by IPA, COUP-TF was reported to play a dual regulatory role in the transcriptional regulation of the mitochondrial HMG-CoA synthase gene: alone COUP-TFI stimulated reporter gene activity from the HMG-CoA synthase promoter in transiently transfected

HepG2 human hepatoma and rat Leydig tumor R2C cells, but it inhibited PPAR α -stimulated transcriptional activity by competing for the same DNA binding site (Rodriguez *et al.* 1997).

Some of the IPA-identified COUP-TFII target gene relationships and mechanisms remain to be fully elucidated. In a study of the transcriptional regulation of murine hepatic development, COUP-TFII occupancy of *Gata6*, *Fxr* (*Nr1h4*), *Pxr* (*Nr1i2*), and *Lrh1* (*Nr5a2*) promoters, as determined by chromatin immunoprecipitation (ChIP) assay, was reported during the postnatal period (Kyrmizi *et al.* 2006). While an inhibitory relationship was suggested for the effect of COUP-TFII on *GATA6*, the effect on *FXR*, *PXR*, and *LRHI* expression is not yet known (Kyrmizi *et al.* 2006). Several other target genes have been identified that highlight the critical function of COUP-TFII in the vascular system. These include an increase in Ang-1 (Pereira *et al.* 1999) and natriuretic peptide A (Huggins *et al.* 2001) by COUP-TFII and a decrease in VEGFR2 and neuropilin 1 (Kang *et al.* 2010). COUP-TFII enhances expression of the NHE1 solute exchanger (Fernandez-Rachubinski & Fliegel 2001, Li *et al.* 2002).

In summary, as indicated by the IPA (Fig. 2) and consistent with previous reports, COUP-TFII plays a role in many downstream pathways and may either activate or suppress gene expression.

Role in the RA pathway

COUP-TFs are classified as orphan members of the NR superfamily because their endogenous ligand(s) is not known. However, Kruse *et al.* (2008) demonstrated *in silico* binding of all-*trans* (atRA) and 9-*cis* (9cRA) RA to the crystal structure of the COUP-TFII ligand-binding domain (LBD). RA released the COUP-TFII LBD from the autorepressed conformation. While the investigators did not directly test binding of all-*trans* or 9-*cis* RA to COUP-TFII, they demonstrated that treatment with atRA or 9cRA increased COUP-TFII interaction with the coactivator SRC-3, with an EC₅₀ of 10–30 μ M. In agreement with this data, addition of 20 μ M atRA or 9cRA led to COUP-TFII's activation of a NGFI-A-luciferase reporter (Kruse *et al.* 2008). Although these concentrations of atRA and 9cRA are greater than the physiological concentration of these retinoids, this finding provides novel insight into the ligand binding ability of COUP-TFII. Indeed, the function of this activation can be seen in the regulation of RAR β 2 by COUP-TFII, as COUP-TFII activation of RAR β 2 expression is increased with the addition of all-*trans* RA (Lin *et al.* 2000, Litchfield *et al.* 2012). Treatment of MCF-7 breast cancer cells with atRA also increased COUP-TFII-binding to the *RARB*2 promoter in a ChIP assay (Litchfield *et al.* 2012). RA induces the expression of COUP-TFII in certain breast cancer cell lines (e.g. T47D and ZR-75) but not others (e.g. MCF-7 and MDA-MB-231) (Fig. 3) (Nakshatri *et al.* 2000, Litchfield *et al.* 2012). This indicates a potential

feed-forward loop, as treatment with RA may increase both the expression and activation of COUP-TFII, with downstream effects on RAR.

Regulation of COUP-TFII expression

Tissue-specific regulation in humans

COUP-TFII has a widespread tissue distribution, with detectable expression in every human tissue type examined (Suzuki *et al.* 2000a). The regulation of COUP-TFII expression is tissue and cell-type specific and can be modulated both transcriptionally and posttranscriptionally (Fig. 3). Hyperinsulinemia is a risk for breast cancer (Gunter *et al.* 2009, Ferguson *et al.* 2012). COUP-TFII expression was repressed by insulin and glucose in the liver and pancreas of C57BL6/J mice and in mouse primary hepatic and pancreatic cell culture (Perilhou *et al.* 2008a). By contrast, we found that insulin treatment had no effect on COUP-TFII expression in MCF-7 and T47D breast cancer cells (Fig. 4). The lack of alteration in COUP-TFII expression with insulin in breast cancer cells highlights the importance of cell-specific regulation of COUP-TFII expression. There are currently no reports on the effect of insulin on COUP-TFII expression in other cancers.

MicroRNA regulation

MicroRNA (miRNA) expression is altered in a variety of conditions and disease states, including cancer, and results in important posttranscriptional regulation of crucial proteins (Lovat *et al.* 2011). While 115 miRNAs are predicted to target *NR2F2* (<http://cometa.tigem.it/site/index.php>), only one miRNA has been verified. miRNA-302 directly represses COUP-TFII expression in human embryonic stem cells (Rosa & Brivanlou 2011). Regulation of COUP-TFII expression by miRNA has not yet been reported in cancer cells.

DNA methylation

Methylation at CpG islands can result in suppression of gene transcription and is known to be a hallmark of cancer progression. DNA methylation may also occur at intragenic and intergenic sites, as well as at the promoter (Deaton & Bird 2011, Shenker & Flanagan 2012). Specifically, COUP-TFII has been found to be methylated in many cancers, including mantle cell lymphoma, acute myeloid leukemia, salivary gland adenoid cystic carcinoma, pancreatic adenocarcinoma, colon cancer, breast cancer ductal carcinoma *in situ*, as well as a tamoxifen-resistant breast cancer cell line (Fan *et al.* 2006, Irizarry *et al.* 2009, Tommasi *et al.* 2009,

Figure 3 Regulation of COUP-TFII expression. COUP-TFII expression has been shown to be modulated both transcriptionally and posttranscriptionally by a variety of transcription factors, signaling pathways, and various molecules, as shown here.

Figure 4 Insulin treatment does not affect COUP-TFII expression in human breast cancer cells. MCF-7 and T47D human breast cancer cells were grown as described in Litchfield *et al.* (2012). As T47D growth media contains 6 mg/ml insulin, T47D cells were grown either in normal media (with insulin) or in insulin-free media to determine whether this affected outcome. Before treatment with insulin, all cells were 'starved' in low glucose media (5 mM glucose) for 24 h (Perilhou *et al.* 2008a,b). Cells were treated for 6 h with the indicated concentrations of insulin. Quantitative RT-PCR was performed to measure *NR2F2* expression relative to GAPDH as a reference gene, as described in Litchfield *et al.* (2012). Insulin treatment had no statistically significant effect on COUP-TFII expression in these cell lines.

Bullinger *et al.* 2010, Bell *et al.* 2011, Enjuanes *et al.* 2011, Vincent *et al.* 2011). *NR2F2* gene hypermethylation was associated with a concordant reduction in mRNA expression in mantle cell lymphoma, pancreatic cancer, and tamoxifen-resistant breast cancer cells (Fan *et al.* 2006, Enjuanes *et al.* 2011, Vincent *et al.* 2011). Whether this indicates a general trend of reduced COUP-TFII

expression due to epigenetic modification across cancer types remains to be seen. Contrary to these reports, high levels of COUP-TFII mRNA expression were found in all cell lines in the NCI60 panel of human cancer cell lines (Holbeck *et al.* 2010).

Regulation by other transcription factors

COUP-TFII and Ets-1 have overlapping expression patterns in mesenchymal cells of the mouse gut, spleen, lungs, and other tissues (Petit *et al.* 2004). Members of the ETS family (Ets-1, Ets-2, ETV, PEA3, Spi-1, and ERM) increased murine COUP-TFII-promoter activity in HeLa cells. Steroid receptor coactivators SRC-1/NCOA1, TIF2/SRC-2/NCOA2, and RAC3/SRC-3/NCOA3 enhanced the activation of the COUP-TFII promoter (Petit *et al.* 2004). In agreement with these data, SRC-3 and RAR α increased COUP-TFII-promoter activity in HepG2 human hepatocellular carcinoma cells with atRA treatment. Reciprocally, siRNA knock-down of SRC-3 repressed COUP-TFII expression (Ma *et al.* 2011). We observed that the protein expression (by immunohistochemical staining) of AIB1/SRC-3/NCOA3, PEA3, and SRC-1/NCOA1 was correlated with COUP-TFII in breast cancer patient samples (Litchfield *et al.* 2012).

Regulation by altered kinase activity and other signaling pathways

Several factors were reported to alter COUP-TFII expression in pathogenic states. More *et al.* reported that expression of COUP-TFII, but not COUP-TFI, is stimulated by activation of the MAPK pathway. Breast cancer cell lines with increased MAPK activity, i.e. SKBR3, had a concomitant increase in COUP-TFII expression (More *et al.* 2003). In contrast to the idea that MAPK activation increases COUP-TFII expression, MAPK has also been shown to phosphorylate and inactivate protein phosphatase 2A (PP2A), leading to a suppression of COUP-TFII expression in human peripheral blood CD34+ cells (Aerbajinai *et al.* 2009). Inactivation of PP2A also inhibits sonic hedgehog-induced COUP-TFII expression in P19 cells (Krishnan *et al.* 1997). PP2A is inhibited by the FOXO transcription factors, including FOXO1 (Ni *et al.* 2007). COUP-TFII expression is induced by FOXO1 in pancreatic β cells and hepatocytes (Perilhou *et al.* 2008a), highlighting the highly cell type-specific nature of these pathways. MAPK activity may lead to increased COUP-TFII expression in certain conditions, while it may alternatively repress COUP-TFII in others. Taken together, these data suggest a possible feedback loop in certain cell types (Fig. 3).

In addition to MAPK activation, Notch signaling is also dysregulated in many types of cancer. Increased Notch signaling has been implicated in carcinogenesis and metastasis and is also involved in regulation of endothelial cell proliferation and angiogenesis (Garcia & Kandel 2012, Gu *et al.* 2012). In breast cancer, Notch and its ligand Jagged1 upregulate the expression of Slug, a transcriptional repressor of E-cadherin important in metastatic progression (Leong *et al.* 2007). Notch signaling has also been implicated in the amplification of HER2 and survival of tumor initiating cells (Magnifico *et al.* 2009) and cancer stem cells (Harrison *et al.* 2010, Pannuti *et al.* 2010, Gu *et al.* 2012). Activation of the Notch pathway confers cancer-like properties and apoptosis resistance to normal breast epithelial cells (Stylianou *et al.* 2006). Regulation of COUP-TFII by Notch signaling has been reported in endothelial cells of both arterial and venous origin and in mouse studies (You *et al.* 2005, Kang *et al.* 2010, Srinivasan *et al.* 2010). Notch can suppress COUP-TFII and Prospero-related homeobox domain 1 (Prox1), leading to an arterial rather than lymphatic phenotype in endothelial cells (Kang *et al.* 2010, Srinivasan *et al.* 2010, Francois *et al.* 2011). COUP-TFII, in turn, can also suppress Notch signaling to result in vein rather than artery formation (You *et al.* 2005). Transforming growth factor β 1 (TGF β 1) suppresses COUP-TFII expression in keratinocytes and fibroblasts leading to induction of collagen type VII (*COL7A1*) expression (Calonge *et al.* 2004) and in vascular progenitor cells to negatively regulate lymph vasculogenesis (Vittet *et al.* 2012). Whether COUP-TFII is regulated via Notch and TGF β 1 signaling has not yet been explored in cancer.

Amplification of Wnt/ β -catenin signaling has been widely reported in cancer (Incassati *et al.* 2010). In normal tissues, β -catenin signaling is controlled through signals leading to its phosphorylation by a multiprotein destruction complex and subsequent degradation. In breast and other cancers, increased expression of Wnt ligands leads to maintenance of β -catenin activation by preventing its degradation (Incassati *et al.* 2010). β -Catenin signaling has many outcomes, such as normal mammary morphogenesis and ductal maturation; however, sustained activation, through a variety of mechanisms, leads to carcinogenesis (Incassati *et al.* 2010). ChIP assays demonstrated that β -catenin/TCF7L2 (T-cell factor 7-like 2 or transcription factor 7-like 2) binds the promoter of COUP-TFII to activate expression, resulting in suppression of adipocyte differentiation (Okamura *et al.* 2009). COUP-TFII is expressed in mouse liver and pancreatic β -cells and plays roles in the maintenance of glucose homeostasis and insulin sensitivity (Bardoux *et al.* 2005, Perilhou *et al.* 2008a). Boutant *et al.* (2012) also reported that β -catenin/TCF7L2 induces COUP-TFII expression in the pancreas and that COUP-TFII

expression was necessary for normal β -cell function and glucose tolerance in mice. The influence of β -catenin signaling on COUP-TFII expression in cancer has yet to be examined.

Role of COUP-TFII in cancer

Angiogenesis

Many studies of COUP-TFII involve its regulation of the angiogenesis pathway. Under normal conditions, angiogenesis is not active after the time of vasculature development during embryogenesis. However, upon progression of a tumor's growth, activation of angiogenesis leads to the formation of new blood vessels to support the tumor (Hanahan & Weinberg 2011). COUP-TFII is necessary during normal development for angiogenesis and lymphangiogenesis, as evidenced by the impaired vessel formation and embryonic lethality in COUP-TFII knockout mice (Pereira *et al.* 1999, Lin *et al.* 2010). The expression of many pro-angiogenic factors is modulated by COUP-TFII, including members of the vascular endothelial growth factor (VEGF) family and their receptors. VEGF induces angiogenesis and lymphangiogenesis by activating tyrosine kinase receptors and upregulates endothelial cell proliferation and migration (Hoebein *et al.* 2004). In a model of pancreatic islet tumorigenesis, ablation of COUP-TFII increased VEGFR1 expression, impairing VEGFR2 signaling and reducing angiogenesis (Qin *et al.* 2010b). Metastasis to regional lymph nodes was reduced as a result, implying that COUP-TFII may have a pro-angiogenic, pro-metastatic role in pancreatic cancer (Qin *et al.* 2010b). Similarly, ablation of COUP-TFII decreased tumorigenesis in B16-F10 melanoma and Lewis lung carcinoma mouse xenografts and reduced tumorigenesis and metastasis in a spontaneous mouse mammary tumor model. These effects were attributed to a decrease in blood vessel density in COUP-TFII-deficient mice (Qin *et al.* 2010a).

In addition to regulating VEGFR expression, COUP-TFII can also affect angiogenesis via regulation of Ang-1, through binding to an Sp1 site in the promoter region. The induction of Ang-1 is partially responsible for the effects of COUP-TFII, as over-expression of Ang-1 allowed for recovery of angiogenesis in COUP-TFII-deficient mice (Qin *et al.* 2010a).

Lymphangiogenesis can also contribute to metastasis by allowing the spread of tumor cells to lymph nodes (Achen *et al.* 2005, Tobler & Detmar 2006). COUP-TFII regulates tumor lymphangiogenesis via inducing expression of VEGF-C and neuropilin-2, a coreceptor for VEGF-C (Nagasaki *et al.* 2009, Lin *et al.* 2010). In a murine model of pancreatic islet tumorigenesis, COUP-TFII deletion resulted in impaired lymphangiogenesis

and reduced metastasis (Qin *et al.* 2010b). Concordant with a role for COUP-TFII in lymphangiogenesis, Kang *et al.* (2010) reported that Notch suppresses COUP-TFII expression, along with Prox1, in human primary dermal lymphatic endothelial cells to signal for arterial rather than lymphatic differentiation. Suppression of COUP-TFII resulted in an increase in VEGF signaling by activating expression of VEGFR2, a VEGF receptor whose signaling can feed back to increase activation of Notch signaling (Kang *et al.* 2010).

COUP-TFII induction by 9cRA was also shown to promote network formation but not cell fusion in SKBR3 breast cancer cells, suggesting a role in the endothelial transdifferentiation pathway as a necessary part of vascular formation (Prahalad *et al.* 2010). Taken together, these data indicate that COUP-TFII may regulate angiogenesis and lymphangiogenesis, primarily through modulation of VEGF and its receptor in a cell context-dependent manner.

Invasion and metastasis

In addition to stimulation of angiogenesis, COUP-TFII may have other distinct roles in regulation of tumor growth and metastasis. Transfection with COUP-TFII in A549, H520, and H441 lung cancer cells and MDA-MB-231 breast cancer cells was reported to increase migration and invasion (Navab *et al.* 2004). Navab *et al.* (2004) found that COUP-TFII upregulated the expression of extracellular matrix-degrading proteinases matrix metalloproteinase 2 (MMP2) and urokinase-type plasminogen activator (uPA). MMP2 and uPA are known to play critical roles in cancer, particularly in angiogenesis and metastasis (Annecke *et al.* 2008). High levels of uPA are predictive of not only recurrence but also a favorable response to adjuvant chemotherapy in breast cancer patients (Harbeck *et al.* 2004). Interestingly, it has also been reported that uPA expression is dependent on Notch signaling in MDA-MB-231, MDA-MB-468, and HCC1143 breast cancer cells (Shimizu *et al.* 2011). COUP-TFII and MMP2 expression were also positively correlated in a breast tumor microarray (Litchfield *et al.* 2012), further indicating a potential relationship between COUP-TFII and extracellular matrix degradation. By contrast, COUP-TFII decreased cell motility when transfected into LY2 tamoxifen-resistant breast cancer cells, while having no significant effect on invasion (Riggs *et al.* 2006).

Estrogen receptor and clinical outcome

Nagasaki *et al.* (2009) demonstrated that COUP-TFII expression was correlated with ER α status and indices of poor clinical outcome (clinical stage, lymph node status, and histological grade) in human breast tumor

samples, indicating that COUP-TFII may play a role in cancer progression. We also found that COUP-TFII and ER α expression were correlated in a human breast tissue/tumor microarray, but instead noted an inverse relationship between COUP-TFII expression and tumor, node, and metastasis (TNM) classification (Litchfield *et al.* 2012). Similar findings were observed at the mRNA level by examining breast tumor mRNA transcriptomes in Oncomine (Litchfield *et al.* 2012). COUP-TFII expression was significantly higher in ER α + breast cancer samples and significantly lower in metastatic samples (Litchfield *et al.* 2012). These findings indicate a function for COUP-TFII in inhibiting tumor progression. A positive correlation with ER α is consistent with a previous report that siRNA knockdown of ER α in MCF-7 breast cancer cells decreased COUP-TFII expression and treatment with estradiol increased the expression of COUP-TFII (Riggs *et al.* 2006). ER α is a positive prognostic factor in breast tumors and is the target of endocrine-targeted cancer therapeutics such as the selective ER modulators (SERMs) tamoxifen and raloxifene (Jordan 2009). COUP-TFII, but not COUP-TFI, is reduced in tamoxifen-resistant human breast cancer cells, and re-expression of COUP-TFII can restore tamoxifen sensitivity (Riggs *et al.* 2006). As ER α expression is important in keeping breast cancer cells responsive to treatment, the correlation of COUP-TFII and ER α further demonstrates a beneficial role for COUP-TFII, highlighting its potential importance in maintaining differentiation and endocrine sensitivity.

In contrast to a role for COUP-TFII in maintaining antiestrogen sensitivity, Holbeck *et al.* (2010) reported that cancer cells in the NCI60 panel expressing low levels of COUP-TFII showed higher sensitivity to microtubule-targeting drugs vinblastine, colchicines, and taxol. These data demonstrate that both cell type-specific as well as drug-specific mechanisms may determine the role of COUP-TFII in influencing treatment response.

Steroidogenesis

COUP-TFII expression was reported to be high in aldosteroma, with an inverse correlation with adrenal steroidogenesis (Suzuki *et al.* 2000b). These data also indicated an inverse correlation between COUP-TFII expression and CYP17A1 expression, with COUP-TFII inhibiting CYP17A1 in aldosteroma (Suzuki *et al.* 2000b). COUP-TFII competed with SF-1 for binding to overlapping sites within the promoters of the *Cyp17a1* (Bakke & Lund 1995, van den Driesche *et al.* 2012), *Cyp11a1*, and *Star* (*STARD1*) genes in rat Leydig cells and to suppress testosterone production (van den Driesche *et al.* 2012). Both COUP-TFI and COUP-TFII repressed angiotensin II-stimulated *STARD1* (*STAR*) in

bovine adrenal glomerulosa cells in primary culture (Buholzer *et al.* 2005). COUP-TFII also competed with SF-1 for the human aromatase P450 promoter II in primary endometriotic stromal cells and suppressed aromatase expression (Zeitoun *et al.* 1999). Overexpression of SF-1 in primary endometriotic stromal cells outcompeted the normal protective effect of COUP-TF (whether COUP-TFI or COUP-TFII involved was unclear as both were equally expressed at the mRNA level), resulting in high local aromatase expression in endometriosis (Zeitoun *et al.* 1999). COUP-TFII was reported to bind the S1 silencer region of the human aromatase gene and suppress transcription in MCF-7 cells (Yang *et al.* 2002). Indeed, the decreases in COUP-TFI, EAR γ , EAR-2, Snail, and Slug in breast cancer were suggested to increase aromatase expression (Chen *et al.* 2005). Thus, the downregulation of COUP-TFII expression that we observed in endocrine-resistant breast cancer cells (Riggs *et al.* 2006) would be expected to increase aromatase and thus increase local estrogen production. However, whether increased COUP-TFII suppresses local androgen or estrogen biosynthesis in breast tissue is unknown. Local conversion of adrenal androgens to estrogens by aromatase is the target of aromatase inhibitor (AI) therapy for postmenopausal women. However, there are androgen metabolites (e.g. 3 β -adiol) that bypass aromatase, which activate ER α and ER β and may play a role in AI resistance (Sikora *et al.* 2009, 2012). Overall, the literature supports a negative role for COUP-TFII in regulating steroid hormone synthesis and further studies addressing COUP-TFII regulation of aromatase gene expression in local estrogen production in breast (Bulun *et al.* 2012) and lung (Marquez-Garban *et al.* 2009) adenocarcinomas would be of merit.

Conclusions

The studies reviewed here indicate that COUP-TFII is regulated and is functionally active to regulate target gene transcription in a cell type-dependent manner. There is evidence that COUP-TFII may perform both pro- and anti-tumorigenic roles. COUP-TFII has been reported to increase angiogenesis and lymphangiogenesis, both increase and decrease tumor metastasis, lead to favorable and unfavorable therapeutic outcome in cancer therapy, and suppress steroidogenesis. Qin *et al.* (2010a) reported that COUP-TFII was not expressed in tumor cells, but rather was found in high concentrations in the surrounding blood vessels that support tumor growth and spread. This indicates a crucial point of consideration about the nature of COUP-TFII in cancer formation and progression: the function of COUP-TFII within cancer cells vs in the surrounding tumor microenvironment and other cell types. Tissue type is

clearly an important determinant in deciphering the oncogenic or tumor-suppressive nature of COUP-TFII. Many studies published to date involve the regulation and role of COUP-TFII during development and in noncancerous disease states. The full applicability of these studies to our knowledge of the role of COUP-TFII in carcinogenesis and cancer progression remains to be seen. Future studies are necessary to elucidate the complex nature of this vital NR.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review reported.

Funding

This work was supported by a grant from Susan G Komen for the Cure KG080365 to C M K. L M L is supported by a fellowship from NIEHS T32 ES011564.

References

- Achen MG, McColl BK & Stacker SA 2005 Focus on lymphangiogenesis in tumor metastasis. *Cancer Cell* **7** 121–127. (doi:10.1016/j.ccr.2005.01.017)
- Aerbajinai W, Zhu J, Kumkhaek C, Chin K & Rodgers GP 2009 SCF induces gamma-globin gene expression by regulating downstream transcription factor COUP-TFII. *Blood* **114** 187–194. (doi:10.1182/blood-2008-07-170712)
- Ahmad N & Kumar R 2011 Steroid hormone receptors in cancer development: a target for cancer therapeutics. *Cancer Letters* **300** 1–9. (doi:10.1016/j.canlet.2010.09.008)
- Anneck K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C & Harbeck N 2008 uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. *Advances in Clinical Chemistry* **45** 31–45. (doi:10.1016/S0065-2423(07)00002-9)
- Bailey PJ, Dowhan DH, Franke K, Burke LJ, Downes M & Muscat GE 1997 Transcriptional repression by COUP-TF II is dependent on the C-terminal domain and involves the N-CoR variant, RIP13delta1. *Journal of Steroid Biochemistry and Molecular Biology* **63** 165–174. (doi:10.1016/S0960-0760(97)00079-4)
- Bakke M & Lund J 1995 Mutually exclusive interactions of two nuclear orphan receptors determine activity of a cyclic adenosine 3',5'-monophosphate-responsive sequence in the bovine CYP17 gene. *Molecular Endocrinology* **9** 327–339. (doi:10.1210/me.9.3.327)
- Bardoux P, Zhang P, Flamez D, Perilhou A, Lavin TA, Tanti JF, Hellems K, Gomas E, Godard C, Andreelli F *et al.* 2005 Essential role of chicken ovalbumin upstream promoter-transcription factor II in insulin secretion and insulin sensitivity revealed by conditional gene knockout. *Diabetes* **54** 1357–1363. (doi:10.2337/diabetes.54.5.1357)
- Bell A, Bell D, Weber RS & El-Naggar AK 2011 CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. *Cancer* **117** 2898–2909. (doi:10.1002/cncr.25818)
- Ben-Shushan E, Sharir H, Pikarsky E & Bergman Y 1995 A dynamic balance between ARP-1/COUP-TFII, EAR-3/COUP-TFI, and retinoic acid receptor:retinoid X receptor heterodimers regulates Oct-3/4 expression in embryonal carcinoma cells. *Molecular and Cellular Biology* **15** 1034–1048.

- Boutant M, Ramos OH, Tourrel-Cuzin C, Movassat J, Ilias A, Vallois D, Planchais J, Pegorier JP, Schuit F, Petit PX *et al.* 2012 COUP-TFII controls mouse pancreatic β -cell mass through GLP-1- β -catenin signaling pathways. *PLoS ONE* **7** e30847. (doi:10.1371/journal.pone.0030847)
- Buholzer CF, Arrighi JF, Abraham S, Piguet V, Capponi AM & Casal AJ 2005 Chicken ovalbumin upstream promoter-transcription factor is a negative regulator of steroidogenesis in bovine adrenal glomerulosa cells. *Molecular Endocrinology* **19** 65–75. (doi:10.1210/me.2004-0061)
- Bullinger L, Ehrich M, Dohner K, Schlenk RF, Dohner H, Nelson MR & van den Boom D 2010 Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. *Blood* **115** 636–642. (doi:10.1182/blood-2009-03-211003)
- Bulun SE, Chen D, Moy I, Brooks DC & Zhao H 2012 Aromatase, breast cancer and obesity: a complex interaction. *Trends in Endocrinology and Metabolism* **23** 83–89. (doi:10.1016/j.tem.2011.10.003)
- Calonge MJ, Seoane J & Massague J 2004 Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor- β . *Journal of Biological Chemistry* **279** 23759–23765. (doi:10.1074/jbc.M402178200)
- Chen S, Ye J, Kijima I, Kinoshita Y & Zhou D 2005 Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. *Journal of Steroid Biochemistry and Molecular Biology* **95** 17–23. (doi:10.1016/j.jsbmb.2005.04.002)
- Chu K & Zingg HH 1997 The nuclear orphan receptors COUP-TFII and Ear-2 act as silencers of the human oxytocin gene promoter. *Journal of Molecular Endocrinology* **19** 163–172. (doi:10.1677/jme.0.0190163)
- Cooney AJ, Leng X, Tsai SY, O'Malley BW & Tsai MJ 1993 Multiple mechanisms of chicken ovalbumin upstream promoter transcription factor-dependent repression of transactivation by the vitamin D, thyroid hormone, and retinoic acid receptors. *Journal of Biological Chemistry* **268** 4152–4160.
- Deaton AM & Bird A 2011 CpG islands and the regulation of transcription. *Genes and Development* **25** 1010–1022. (doi:10.1101/gad.2037511)
- De Martino MU, Alesci S, Chrousos GP & Kino T 2004a Interaction of the glucocorticoid receptor and the chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII): implications for the actions of glucocorticoids on glucose, lipoprotein, and xenobiotic metabolism. *PNAS* **102** 72–85. (doi:10.1196/annals.1321.006)
- De Martino MU, Bhattacharyya N, Alesci S, Ichijo T, Chrousos GP & Kino T 2004b The glucocorticoid receptor and the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II interact with and mutually affect each other's transcriptional activities: implications for intermediary metabolism. *Molecular Endocrinology* **18** 820–833. (doi:10.1210/me.2003-0341)
- van den Driesche S, Walker M, McKinnell C, Scott HM, Eddie SL, Mitchell RT, Seckl JR, Drake AJ, Smith LB, Anderson RA *et al.* 2012 Proposed role for COUP-TFII in regulating fetal leydig cell steroidogenesis, perturbation of which leads to masculinization disorders in rodents. *PLoS ONE* **7** e37064. (doi:10.1371/journal.pone.0037064)
- Enjuanes A, Fernandez V, Hernandez L, Navarro A, Bea S, Pinyol M, Lopez-Guillermo A, Rosenwald A, Ott G, Campo E *et al.* 2011 Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. *PLoS ONE* **6** e19736. (doi:10.1371/journal.pone.0019736)
- Eubank DW, Duplus E, Williams SC, Forest C & Beale EG 2001 Peroxisome proliferator-activated receptor γ and chicken ovalbumin upstream promoter transcription factor II negatively regulate the phosphoenolpyruvate carboxykinase promoter via a common element. *Journal of Biological Chemistry* **276** 30561–30569. (doi:10.1074/jbc.M103019200)
- Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH *et al.* 2006 Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. *Cancer Research* **66** 11954–11966. (doi:10.1158/0008-5472.CAN-06-1666)
- Ferguson R, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S & LeRoith D 2012 Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. *Breast Cancer Research* **14** R8. (doi:10.1186/bcr3089)
- Fernandez-Rachubinski F & Fliegel I 2001 COUP-TFI and COUP-TFII regulate expression of the NHE through a nuclear hormone responsive element with enhancer activity. *European Journal of Biochemistry* **268** 620–634. (doi:10.1046/j.1432-1327.2001.01915.x)
- Francois M, Harvey NL & Hogan BM 2011 The transcriptional control of lymphatic vascular development. *Physiology* **26** 146–155. (doi:10.1152/physiol.00053.2010)
- Garcia A & Kandel JJ 2012 Notch: a key regulator of tumor angiogenesis and metastasis. *Histology and Histopathology* **27** 151–156.
- Gu JW, Rizzo P, Pannuti A, Golde T, Osborne B & Miele L 2012 Notch signals in the endothelium and cancer “stem-like” cells: opportunities for cancer therapy. *Vascular Cell* **4** 7. (doi:10.1186/2045-824X-4-7)
- Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL *et al.* 2009 Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. *Journal of the National Cancer Institute* **101** 48–60. (doi:10.1093/jnci/djn415)
- Hammond GL 2011 Diverse roles for sex hormone-binding globulin in reproduction. *Biology of Reproduction* **85** 431–441. (doi:10.1095/biolreprod.111.092593)
- Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. *Cell* **144** 646–674. (doi:10.1016/j.cell.2011.02.013)
- Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP & Foekens JA 2004 Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. *Clinical Breast Cancer* **5** 348–352. (doi:10.3816/CBC.2004.n.040)
- Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ & Clarke RB 2010 Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. *Cancer Research* **70** 709–718. (doi:10.1158/0008-5472.CAN-09-1681)
- Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT & De Bruijn EA 2004 Vascular endothelial growth factor and angiogenesis. *Pharmacological Reviews* **56** 549–580. (doi:10.1124/pr.56.4.3)
- Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ & Martinez ED 2010 Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. *Molecular Endocrinology* **24** 1287–1296. (doi:10.1210/me.2010-0040)
- Huggins GS, Bacani CJ, Boltax J, Aikawa R & Leiden JM 2001 Friend of GATA 2 physically interacts with chicken ovalbumin upstream promoter-TF2 (COUP-TF2) and COUP-TF3 and represses COUP-TF2-dependent activation of the atrial natriuretic factor promoter. *Journal of Biological Chemistry* **276** 28029–28036. (doi:10.1074/jbc.M103577200)
- Incassati A, Chandramouli A, Eelkema R & Cowin P 2010 Key signaling nodes in mammary gland development and cancer: β -catenin. *Breast Cancer Research* **12** 213. (doi:10.1186/bcr2723)
- Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M *et al.* 2009 The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. *Nature Genetics* **41** 178–186. (doi:10.1038/ng.298)

- Janne M & Hammond GL 1998 Hepatocyte nuclear factor-4 controls transcription from a TATA-less human sex hormone-binding globulin gene promoter. *Journal of Biological Chemistry* **273** 34105–34114. (doi:10.1074/jbc.273.51.34105)
- Jiang G, Nepomuceno L, Hopkins K & Sladek FM 1995 Exclusive homodimerization of the orphan receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors. *Molecular and Cellular Biology* **15** 5131–5143.
- Jordan VC 2009 A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. *Cancer Research* **69** 1243–1254. (doi:10.1158/0008-5472.CAN-09-0029)
- Kang J, Yoo J, Lee S, Tang W, Aguilar B, Ramu S, Choi I, Otu HH, Shin JW, Dotto GP *et al.* 2010 An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. *Blood* **116** 140–150. (doi:10.1182/blood-2009-11-252270)
- Kliwer SA, Umesono K, Heyman RA, Mangelsdorf DJ, Dyck JA & Evans RM 1992 Retinoid X receptor–COUP-TF interactions modulate retinoic acid signaling. *PNAS* **89** 1448–1452. (doi:10.1073/pnas.89.4.1448)
- Klinge CM, Silver BF, Driscoll MD, Sathya G, Bambara RA & Hilf R 1997 Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. *Journal of Biological Chemistry* **272** 31465–31474. (doi:10.1074/jbc.272.50.31465)
- Krishnan V, Pereira FA, Qiu Y, Chen CH, Beachy PA, Tsai SY & Tsai MJ 1997 Mediation of Sonic hedgehog-induced expression of COUP-TFII by a protein phosphatase. *Science* **278** 1947–1950. (doi:10.1126/science.278.5345.1947)
- Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, Vonrhein C, Xu Y, Wang L, Tsai SY, Tsai MJ *et al.* 2008 Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. *PLoS Biology* **6** e227. (doi:10.1371/journal.pbio.0060227)
- Ktistaki E & Talianidis I 1997 Chicken ovalbumin upstream promoter transcription factor acts as auxiliary cofactors for hepatocyte nuclear factor 4 and enhance hepatic gene expression. *Molecular and Cellular Biology* **17** 2790–2797.
- Kurihara I, Shibata H, Kobayashi S, Suda N, Ikeda Y, Yokota K, Murai A, Saito I, Rainey WE & Saruta T 2005 Ubc9 and protein inhibitor of activated STAT 1 activate chicken ovalbumin upstream promoter-transcription factor I-mediated human CYP11B2 gene transcription. *Journal of Biological Chemistry* **280** 6721–6730. (doi:10.1074/jbc.M411820200)
- Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ & Talianidis I 2006 Plasticity and expanding complexity of the hepatic transcription factor network during liver development. *Genes and Development* **20** 2293–2305. (doi:10.1101/gad.390906)
- Lavrentiadou SN, Hadzopoulou-Cladaras M, Kardassis D & Zannis VI 1999 Binding specificity and modulation of the human ApoCIII promoter activity by heterodimers of ligand-dependent nuclear receptors. *Biochemistry* **38** 964–975. (doi:10.1021/bi981068i)
- Lee MO, Liu Y & Zhang XK 1995 A retinoic acid response element that overlaps an estrogen response element mediates multihormonal sensitivity in transcriptional activation of the lactoferrin gene. *Molecular and Cellular Biology* **15** 4194–4207.
- Lee CT, Li L, Takamoto N, Martin JF, Demayo FJ, Tsai MJ & Tsai SY 2004 The nuclear orphan receptor COUP-TFII is required for limb and skeletal muscle development. *Molecular and Cellular Biology* **24** 10835–10843. (doi:10.1128/MCB.24.24.10835-10843.2004)
- Lee KN, Jang WG, Kim EJ, Oh SH, Son HJ, Kim SH, Franceschi R, Zhang XK, Lee SE & Koh JT 2012 Orphan nuclear receptor COUP-TFII negatively regulates BMP2-induced osteoblast differentiation through suppressing Runx2 activity. *Journal of Biological Chemistry* **287** 18888–18899.
- Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I & Karsan A 2007 Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. *Journal of Experimental Medicine* **204** 2935–2948. (doi:10.1084/jem.20071082)
- Li X, Misik AJ, Rieder CV, Solaro RJ, Lowen A & Fliegel L 2002 Thyroid hormone receptor $\alpha 1$ regulates expression of the Na⁺/H⁺ exchanger (NHE1). *Journal of Biological Chemistry* **277** 28656–28662. (doi:10.1074/jbc.M203221200)
- Liberati C, Cera MR, Secco P, Santoro C, Mantovani R, Ottolenghi S & Ronchi A 2001 Cooperation and competition between the binding of COUP-TFII and NF- κ B on human epsilon- and gamma-globin gene promoters. *Journal of Biological Chemistry* **276** 41700–41709. (doi:10.1074/jbc.M102987200)
- Lin B, Chen GQ, Xiao D, Kolluri SK, Cao X, Su H & Zhang XK 2000 Orphan receptor COUP-TF is required for induction of retinoic acid receptor β , growth inhibition, and apoptosis by retinoic acid in cancer cells. *Molecular and Cellular Biology* **20** 957–970. (doi:10.1128/MCB.20.3.957-970.2000)
- Lin F, Kolluri SK, Chen GQ & Zhang XK 2002 Regulation of retinoic acid-induced inhibition of AP-1 activity by orphan receptor chicken ovalbumin upstream promoter-transcription factor. *Journal of Biological Chemistry* **277** 21414–21422. (doi:10.1074/jbc.M201885200)
- Lin FJ, Chen X, Qin J, Hong YK, Tsai MJ & Tsai SY 2010 Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel development. *Journal of Clinical Investigation* **120** 1694–1707. (doi:10.1172/JCI40101)
- Lin FJ, Qin J, Tang K, Tsai SY & Tsai MJ 2011 Coup d'Etat: an orphan takes control. *Endocrine Reviews* **32** 404–421.
- Litchfield LM, Riggs KA, Hockenberry AM, Oliver LD, Barnhart KG, Cai J, Pierce WM Jr, Ivanova MM, Bates PJ, Appana SN *et al.* 2012 Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells. *PLoS ONE* **7** e38278. (doi:10.1371/journal.pone.0038278)
- Lovat F, Valeri N & Croce CM 2011 MicroRNAs in the pathogenesis of cancer. *Seminars in Oncology* **38** 724–733. (doi:10.1053/j.seminoncol.2011.08.006)
- Ma X, Xu L, Wang S, Cui B, Li X, Xu J & Ning G 2011 Deletion of steroid receptor coactivator-3 gene ameliorates hepatic steatosis. *Journal of Hepatology* **55** 445–452. (doi:10.1016/j.jhep.2010.11.022)
- Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S & Tagliabue E 2009 Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. *Clinical Cancer Research* **15** 2010–2021. (doi:10.1158/1078-0432.CCR-08-1327)
- Marcus SL, Winrow CJ, Capone JP & Rachubinski RA 1996 A p56(lck) ligand serves as a coactivator of an orphan nuclear hormone receptor. *Journal of Biological Chemistry* **271** 27197–27200. (doi:10.1074/jbc.271.44.27197)
- Marquez-Garban DC, Chen HW, Goodlick L, Fishbein MC & Pietras RJ 2009 Targeting aromatase and estrogen signaling in human non-small cell lung cancer. *Annals of the New York Academy of Sciences* **1155** 194–205. (doi:10.1111/j.1749-6632.2009.04116.x)
- Mietus-Snyder M, Sladek FM, Ginsburg GS, Kuo CF, Ladias JA, Darnell JE Jr & Karathanasis SK 1992 Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells. *Molecular and Cellular Biology* **12** 1708–1718.
- More E, Fellner T, Doppelmayr H, Hauser-Kronberger C, Dandachi N, Obrist P, Sandhofer F & Paulweber B 2003 Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines. *Journal of Endocrinology* **176** 83–94. (doi:10.1677/joe.0.1760083)
- Nagasaki S, Suzuki T, Miki Y, Akahira J, Shibata H, Ishida T, Ohuchi N & Sasano H 2009 Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible

- regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. *Cancer Science* **100** 639–645. (doi:10.1111/j.1349-7006.2008.01078.x)
- Nakshatri H & Chambon P 1994 The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinoid-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo- and heterodimers. *Journal of Biological Chemistry* **269** 890–902.
- Nakshatri H, Mendonca MS, Bhat-Nakshatri P, Patel NM, Goulet RJ Jr & Cornetta K 2000 The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. *Biochemical and Biophysical Research Communications* **270** 1144–1153. (doi:10.1006/bbrc.2000.2562)
- Navab R, Gonzalez-Santos JM, Johnston MR, Liu J, Brodt P, Tsao MS & Hu J 2004 Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells. *Cancer Research* **64** 5097–5105. (doi:10.1158/0008-5472.CAN-03-1185)
- Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD, Kuro OM, Rothermel BA & Hill JA 2007 FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. *PNAS* **104** 20517–20522. (doi:10.1073/pnas.0610290104)
- Ochoa A, Bovard-Houppermans S & Zakin MM 1993 Human apolipoprotein A-IV gene expression is modulated by members of the nuclear hormone receptor superfamily. *Biochimica et Biophysica Acta* **1210** 41–47. (doi:10.1016/0005-2760(93)90047-D)
- Okamura M, Kudo H, Wakabayashi K, Tanaka T, Nonaka A, Uchida A, Tsutsumi S, Sakakibara I, Naito M, Osborne TF *et al.* 2009 COUP-TFII acts downstream of Wnt/ β -catenin signal to silence PPAR γ gene expression and repress adipogenesis. *PNAS* **106** 5819–5824. (doi:10.1073/pnas.0901676106)
- Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B & Miele L 2010 Targeting Notch to target cancer stem cells. *Clinical Cancer Research* **16** 3141–3152. (doi:10.1158/1078-0432.CCR-09-2823)
- Pereira FA, Qiu Y, Zhou G, Tsai MJ & Tsai SY 1999 The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. *Genes and Development* **13** 1037–1049. (doi:10.1101/gad.13.8.1037)
- Perillou A, Tourrel-Cuzin C, Kharroubi I, Henique C, Fauveau V, Kitamura T, Magnan C, Postic C, Prip-Buus C & Vasseur-Cognet M 2008a The transcription factor COUP-TFII is negatively regulated by insulin and glucose via Foxo1- and ChREBP-controlled pathways. *Molecular and Cellular Biology* **28** 6568–6579. (doi:10.1128/MCB.02211-07)
- Perillou A, Tourrel-Cuzin C, Zhang P, Kharroubi I, Wang H, Fauveau V, Scott DK, Wollheim CB & Vasseur-Cognet M 2008b The MODY1 gene for hepatocyte nuclear factor 4 α and a feedback loop control COUP-TFII expression in pancreatic β cells. *Molecular and Cellular Biology* **28** 4588–4597. (doi:10.1128/MCB.01191-07)
- Petit FG, Salas R, Tsai MJ & Tsai SY 2004 The regulation of COUP-TFII gene expression by Ets-1 is enhanced by the steroid receptor co-activators. *Mechanisms of Ageing and Development* **125** 719–732. (doi:10.1016/j.mad.2004.03.009)
- Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC & Staels B 2002 Characterization of the human PPAR α promoter: identification of a functional nuclear receptor response element. *Molecular Endocrinology* **16** 1013–1028. (doi:10.1210/me.16.5.1013)
- Pipaon C, Tsai SY & Tsai MJ 1999 COUP-TF upregulates NGFI-A gene expression through an Sp1 binding site. *Molecular and Cellular Biology* **19** 2734–2745.
- Power SC & Cereghini S 1996 Positive regulation of the vHNF1 promoter by the orphan receptors COUP-TF1/Ear3 and COUP-TFII/Arp1. *Molecular and Cellular Biology* **16** 778–791.
- Prahalad P, Dakshanamurthy S, Resson H & Byers SW 2010 Retinoic acid mediates regulation of network formation by COUP-TFII and VE-cadherin expression by TGF β receptor kinase in breast cancer cells. *PLoS ONE* **5** e10023. (doi:10.1371/journal.pone.0010023)
- Qin J, Chen X, Xie X, Tsai MJ & Tsai SY 2010a COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis. *PNAS* **107** 3687–3692. (doi:10.1073/pnas.0914619107)
- Qin J, Chen X, Yu-Lee LY, Tsai MJ & Tsai SY 2010b Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. *Cancer Research* **70** 8812–8821. (doi:10.1158/0008-5472.CAN-10-0551)
- Riggs KA, Wickramasinghe NS, Cochrum RK, Watts MB & Klinge CM 2006 Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. *Cancer Research* **66** 10188–10198. (doi:10.1158/0008-5472.CAN-05-3937)
- Risbridger GP, Davis ID, Birrell SN & Tilley WD 2010 Breast and prostate cancer: more similar than different. *Nature Reviews. Cancer* **10** 205–212. (doi:10.1038/nrc2795)
- Robinson CE, Wu X, Nawaz Z, Onate SA & Gimble JM 1999 A corepressor and chicken ovalbumin upstream promoter transcriptional factor proteins modulate peroxisome proliferator-activated receptor- γ 2/retinoid X receptor α -activated transcription from the murine lipoprotein lipase promoter. *Endocrinology* **140** 1586–1593. (doi:10.1210/en.140.4.1586)
- Rodriguez JC, Ortiz JA, Hegardt FG & Haro D 1997 Chicken ovalbumin upstream-promoter transcription factor (COUP-TF) could act as a transcriptional activator or repressor of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene. *Biochemical Journal* **326** 587–592.
- Rosa A & Brivanlou AH 2011 A regulatory circuitry comprised of miR-302 and the transcription factors OCT4 and NR2F2 regulates human embryonic stem cell differentiation. *EMBO Journal* **30** 237–248. (doi:10.1038/emboj.2010.319)
- Rufibach LE, Duncan SA, Battle M & Deeb SS 2006 Transcriptional regulation of the human hepatic lipase (LIPC) gene promoter. *Journal of Lipid Research* **47** 1463–1477. (doi:10.1194/jlr.M600082-JLR200)
- Sagami I, Tsai SY, Wang H, Tsai MJ & O'Malley BW 1986 Identification of two factors required for transcription of the ovalbumin gene. *Molecular and Cellular Biology* **6** 4259–4267.
- Sauvaget D, Chauffeton V, Citadelle D, Chatelet FP, Cywiner-Golenzer C, Chambaz J, Pincon-Raymond M, Cardot P, Le Beyec J & Ribeiro A 2002 Restriction of apolipoprotein A-IV gene expression to the intestine villus depends on a hormone-responsive element and parallels differential expression of the hepatic nuclear factor 4 α and γ isoforms. *Journal of Biological Chemistry* **277** 34540–34548. (doi:10.1074/jbc.M206074200)
- Selva DM, Hogeveen KN & Hammond GL 2005 Repression of the human sex hormone-binding globulin gene in Sertoli cells by upstream stimulatory transcription factors. *Journal of Biological Chemistry* **280** 4462–4468. (doi:10.1074/jbc.M409616200)
- Shenker N & Flanagan JM 2012 Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. *British Journal of Cancer* **106** 248–253. (doi:10.1038/bjc.2011.550)
- Shibata H, Nawaz Z, Tsai SY, O'Malley BW & Tsai MJ 1997 Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT). *Molecular Endocrinology* **11** 714–724. (doi:10.1210/me.11.6.714)
- Shibata H, Kobayashi S, Kurihara I, Suda N, Yokota K, Murai A, Ikeda Y, Saito I, Rainey WE & Saruta T 2004 COUP-TF and transcriptional co-regulators in adrenal steroidogenesis. *Endocrine Research* **30** 795–801. (doi:10.1081/ERC-200044042)
- Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C & Reedijk M 2011 Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. *Cancer Research* **71** 277–286. (doi:10.1158/0008-5472.CAN-10-2523)

- Siddikuzzaman, Guruvayoorappan C & Berlin Grace VM 2011 All *trans* retinoic acid and cancer. *Immunopharmacology and Immunotoxicology* **33** 241–249. (doi:10.3109/08923973.2010.521507)
- Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME & Rae JM 2009 The androgen metabolite 5 α -androstan-3 β ,17 β -diol (3 β adiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. *Breast Cancer Research and Treatment* **115** 289–296. (doi:10.1007/s10549-008-0080-8)
- Sikora MJ, Strumba V, Lippman ME, Johnson MD & Rae JM 2012 Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. *Breast Cancer Research and Treatment* **134** 1027–1039.
- Srinivasan RS, Geng X, Yang Y, Wang Y, Mukatira S, Studer M, Porto MP, Lagutin O & Oliver G 2010 The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. *Genes and Development* **24** 696–707. (doi:10.1101/gad.1859310)
- Stanisic V, Lonard DM & O'Malley BW 2010 Modulation of steroid hormone receptor activity. *Progress in Brain Research* **181** 153–176. (doi:10.1016/S0079-6123(08)81009-6)
- Stroup D & Chiang JY 2000 HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7 α -hydroxylase gene (CYP7A1). *Journal of Lipid Research* **41** 1–11.
- Stylianou S, Clarke RB & Brennan K 2006 Aberrant activation of Notch signaling in human breast cancer. *Cancer Research* **66** 1517–1525. (doi:10.1158/0008-5472.CAN-05-3054)
- Suzuki T, Moriya T, Darnel AD, Takeyama J & Sasano H 2000a Immunohistochemical distribution of chicken ovalbumin upstream promoter transcription factor II in human tissues. *Molecular and Cellular Endocrinology* **164** 69–75. (doi:10.1016/S0303-7207(00)00242-2)
- Suzuki T, Takahashi K, Darnel AD, Moriya T, Murakami O, Narasaka T, Takeyama J & Sasano H 2000b Chicken ovalbumin upstream promoter transcription factor II in the human adrenal cortex and its disorders. *Journal of Clinical Endocrinology and Metabolism* **85** 2752–2757. (doi:10.1210/jc.85.8.2752)
- Tang K, Xie X, Park JI, Jamrich M, Tsai S & Tsai MJ 2010 COUP-TFs regulate eye development by controlling factors essential for optic vesicle morphogenesis. *Development* **137** 725–734. (doi:10.1242/dev.040568)
- Tanimoto K, Liu Q, Grosveld F, Bungert J & Engel JD 2000 Context-dependent EKLF responsiveness defines the developmental specificity of the human epsilon-globin gene in erythroid cells of YAC transgenic mice. *Genes and Development* **14** 2778–2794. (doi:10.1101/gad.822500)
- Thornton JW 2001 Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. *PNAS* **98** 5671–5676. (doi:10.1073/pnas.091553298)
- Thornton JW, Need E & Crews D 2003 Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. *Science* **301** 1714–1717. (doi:10.1126/science.1086185)
- Tobler NE & Detmar M 2006 Tumor and lymph node lymphangiogenesis – impact on cancer metastasis. *Journal of Leukocyte Biology* **80** 691–696. (doi:10.1189/jlb.1105653)
- Tommasi S, Karm DL, Wu X, Yen Y & Pfeifer GP 2009 Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. *Breast Cancer Research* **11** R14. (doi:10.1186/bcr2233)
- Tsai SY & Tsai MJ 1997 Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. *Endocrine Reviews* **18** 229–240. (doi:10.1210/er.18.2.229)
- Vasyutina E & Birchmeier C 2006 The development of migrating muscle precursor cells. *Anatomy and Embryology* **211** (Suppl 1) 37–41. (doi:10.1007/s00429-006-0118-9)
- Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J & Goggins M 2011 Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. *Clinical Cancer Research* **17** 4341–4354. (doi:10.1158/1078-0432.CCR-10-3431)
- Vittet D, Merdzhanova G, Prandini MH, Feige JJ & Bailly S 2012 TGF β 1 inhibits lymphatic endothelial cell differentiation from mouse embryonic stem cells. *Journal of Cellular Physiology* **227** 3593–3602.
- Widom RL, Rhee M & Karathanasis SK 1992 Repression by ARP-1 sensitizes apolipoprotein AI gene responsiveness to RXR α and retinoic acid. *Molecular and Cellular Biology* **12** 3380–3389.
- Wu Q, Li Y, Liu R, Agadir A, Lee MO, Liu Y & Zhang X 1997 Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. *EMBO Journal* **16** 1656–1669. (doi:10.1093/emboj/16.7.1656)
- Yang C, Yu B, Zhou D & Chen S 2002 Regulation of aromatase promoter activity in human breast tissue by nuclear receptors. *Oncogene* **21** 2854–2863. (doi:10.1038/sj.onc.1205386)
- You M, Fischer M, Cho WK & Crabb D 2002 Transcriptional control of the human aldehyde dehydrogenase 2 promoter by hepatocyte nuclear factor 4: inhibition by cyclic AMP and COUP transcription factors. *Archives of Biochemistry and Biophysics* **398** 79–86. (doi:10.1006/abbi.2001.2713)
- You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ & Tsai SY 2005 Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. *Nature* **435** 98–104. (doi:10.1038/nature03511)
- Yu RN, Ito M & Jameson JL 1998 The murine Dax-1 promoter is stimulated by SF-1 (steroidogenic factor-1) and inhibited by COUP-TF (chicken ovalbumin upstream promoter-transcription factor) via a composite nuclear receptor-regulatory element. *Molecular Endocrinology* **12** 1010–1022. (doi:10.1210/me.12.7.1010)
- Zeitoun K, Takayama K, Michael MD & Bulun SE 1999 Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. *Molecular Endocrinology* **13** 239–253. (doi:10.1210/me.13.2.239)
- Zhang LJ, Liu X, Gafken PR, Kiousi C & Leid M 2009 A chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor α -induced protein 8 (TNFAIP8). *Journal of Biological Chemistry* **284** 6156–6168. (doi:10.1074/jbc.M807713200)

Received in final form 21 August 2012

Accepted 10 September 2012

Made available online as an Accepted Preprint
10 September 2012